Tata Capital Innovations Fund, a domestic venture capital fund managed by Tata Capital has invested in Mitra Biotech Private Ltd, to help the company scale up its go to market strategy and to expand in India & globally.
The investment would help Mitra become a partner of choice for leading healthcare providers, pharmaceutical & biotech companies by strengthening its business development, marketing and R&D teams.
Mitra Biotech, a company headquartered in Bangalore (India), is a translational biology company focused on offering personalized cancer care to patients through its proprietary patient segregation model Oncoprint. This technology determines the optimal drug or drug combination for a patient under investigation, thereby reducing overall treatment cycle and avoiding toxicity that arises from non-optimal drugs. The assays are carried out on patients’ own tumors by recreating human-tumor microenvironment on plates to ensure high specificity.
Mitra Biotech earlier raised funding from Accel Partners, KITVEN and India Innovations fund. Mitra has partnered with leading cancer hospitals like Tata Memorial Hospital, Mazumdar Shaw Cancer Center, Kidwai Memorial Center, Stanley Medical Center and HCG Cancer Network centers in bringing affordable cancer care to India.